We're off to the races!

Bioverativ Highlights the Impact of Humanitarian Aid in Hemophilia

Industry News
The following is an excerpt from a press release from Bioverativ. Read the entire press release here. 


More than 15,000 people with hemophilia in 40 developing countries have already been treated following Bioverativ and Sobi’s unprecedented donation of factor therapy to the WFH Humanitarian Aid Program

Bioverativ Inc., a Sanofi company, joins the global hemophilia community in recognizing World Hemophilia Day 2018. To honor this year’s theme, Sharing Knowledge Makes Us Stronger, Bioverativ is sharing the stories of people with hemophilia in the developing world and highlighting the life-changing impact treatment can make.
In 2014, Bioverativ and Swedish Orphan Biovitrum AB (publ) (Sobi) pledged to donate up to one billion international units (IUs) of clotting factor over 10 years, including up to 500 million IUs to the WFH Humanitarian Aid Program over a period up to five years, to help transform the way hemophilia care is delivered in the developing world. Since donations began in 2015, more than 15,000 people with hemophilia in 40 countries have already been treated with over 260 million IUs of medicine donated by Bioverativ and Sobi to the WFH Humanitarian Aid Program. The far-reaching impact of this donation includes:

  • Nearly tripling the percentage of children receiving treatment from 14% to 39% of patients treated
  • Providing prophylactic treatment to ~1,200 people, two-thirds of whom are children under the age of 10
  • Treating approximately 79,500 acute bleeds
  • Enabling more than 1,500 surgeries, including life- and limb-saving

“I have witnessed the profound impact that donated factor has on those living with hemophilia in developing countries, and we thank Bioverativ and Sobi for their visionary leadership,” said Alain Weill, WFH President. “Whether for acute bleeds or prophylactic treatment, or to enable necessary surgeries, these donations are life-changing for patients and their families.”
 
Read the entire press release here. 

Read more news.

en_USEnglish